Lantern Pharma falls out of Nasdaq MVLS compliance after market value stays below $35 million
LTRN•LTRN•LTRN•LTRN•Lantern Pharma received a Nasdaq notice after its market value of listed securities stayed below $35 million for 30 business days. It has until March 24, 2027, to regain compliance or could face a delisting notice.
Nasdaq notified Lantern Pharma that it was not in compliance with Listing Rule 5550(b)(2) after its market value of listed securities remained below $35 million for 30 business days. Nasdaq also flagged that the company does not meet requirements under Listing Rules 5550(b)(1) and 5550(b)(3). To cure the market-value breach, the measure must close at or above $35 million for at least 10 consecutive business days. Lantern has until March 24, 2027, to regain compliance; failure could trigger a delisting notice for its securities from the Nasdaq Capital Market.
